Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins
| Autor: | Aeilko H. Zwinderman, Ivana Bobeldijk, Theo H. Reijmers, Sandrin C. Bergheanu, Thomas Hankemeier, Anho Liem, Raymond Ramaker, J. Wouter Jukema, Jan van der Greef |
|---|---|
| Přispěvatelé: | APH - Amsterdam Public Health, Epidemiology and Data Science |
| Jazyk: | angličtina |
| Rok vydání: | 2008 |
| Předmět: |
Atorvastatin
Pharmacology Mass Spectrometry Coronary artery disease Efficacy chemistry.chemical_compound Lipidomics medicine Humans Pyrroles Rosuvastatin Prospective Studies Rosuvastatin Calcium Sulfonamides Dose-Response Relationship Drug medicine.diagnostic_test Cholesterol business.industry nutritional and metabolic diseases Lipid metabolism General Medicine medicine.disease Lipids Fluorobenzenes Pyrimidines chemistry Heptanoic Acids lipids (amino acids peptides and proteins) Hydroxymethylglutaryl-CoA Reductase Inhibitors Lipid profile business Chromatography Liquid medicine.drug |
| Zdroj: | Current medical research and opinion, 24(9), 2477-2487. Taylor and Francis Ltd. |
| ISSN: | 0300-7995 |
| DOI: | 10.1185/03007990802321709 |
| Popis: | Objective: Lipid profiling (lipidomics) may be useful in revealing detailed information with regard to the effects on lipid metabolism, the cardiovascular risk and to differentiate between therapies. The aims of the present study were to: (1) analyze in depth the lipid changes induced by rosuvastatin and atorvastatin at different dosages; (2) compare differences between the two drugs with respect to the lipid profile change; (3) relate the findings with meaningful pathological mechanisms of coronary artery disease. Research design and methods: Liquid chromatography-mass spectrometry was applied to obtain the metabolite profiles of plasma samples taken from a prospectively defined subset (n = 80) of participants in the RADAR study where a randomly assigned treatment with rosuvastatin or atorvastatin in increasing dosages was administered during an 18-week period. Results: A number of sphingomyelins (SPMs) and phosphatidylcholines (PGs) correlate with the different effects of the two statins on the LDL-C/HDL-C ratio. Rosuvastatin increased the plasma concentration of PCs after 6 and 18 weeks, while atorvastatin reduced the plasma concentrations of PCs at both timepoints and dosages (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|